Cargando…
6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
BACKGROUND: Meningococcal serogroups A, B, C, W and Y cause nearly all meningococcal disease globally. Vaccination is complicated by different dosing recommendations for serogroup B (MenB) and quadrivalent (MenACWY) vaccines, which could be solved with a single pentavalent vaccine. This study in ado...
Autores principales: | Peterson, James, Drazan, Daniel, Czajka, Hanna, Maguire, Jason, Pregaldien, Jean-Louis, Seppa, Ilkka, Maansson, Roger, O’Neill, Robert, Anderson, Annaliesa S, Balmer, Paul, Beeslaar, Johannes, Perez, John L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776022/ http://dx.doi.org/10.1093/ofid/ofaa439.051 |
Ejemplares similares
-
Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults
por: Beran, Jiří, et al.
Publicado: (2021) -
1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine
por: Cai, Bing, et al.
Publicado: (2023) -
1146. Cost-effectiveness of the Pentavalent Meningococcal Vaccine (MenABCWY): A steady-state cohort modelling approach
por: Schley, Katharina, et al.
Publicado: (2023) -
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies
por: Beeslaar, Johannes, et al.
Publicado: (2020) -
1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)